SCPHARMACEUTICALS INC (SCPH)

Company Profile

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 96 full-time employees. The company went IPO on 2017-11-17. The firm is focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The firm develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for the treatment of edema in adult patients with congestive heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome. Its pipeline programs also include scCeftriaxone and scCarbapenem. Its scCeftriaxone is an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. Its scCarbapenem program is an antibiotic used intravenously for the treatment of infections caused by gram-negative organisms.

Company Info

SCPHARMACEUTICALS INC

25 Burlington Mall Road, Suite 203

Burlington MASSACHUSETTS 01803

P: 16175170730

CEO: John H. Tucker

Employees: 96

Website: https://www.scpharmaceuticals.com/